Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant
RecruitingObservational study
A Prospective, Registry-based, Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant: The Migraine Observational Nurtec Pregnancy Registry (MONITOR)
Who can join
Ages 0 and older · Women
Full eligibility criteria
Inclusion Criteria: * Pregnant women with migraine exposed to rimegepant: a diagnosis of migraine and at least 1 dose of rimegepant during pregnancy or just prior to pregnancy (up to 3 days prior to conception) * Pregnant women with migraine unexposed to rimegepant: a diagnosis of migraine and no exposure to Rimegepant before or during pregnancy Exclusion Criteria: • Women exposed to other calcitonin gene-related peptide (CGRP)antagonists (e.g., ubrogepant), CGRP monoclonal antibodies, or ditans (e.g., lasmiditan) at any time during pregnancy or just prior to pregnancy
About the study
The purpose of the study is to evaluate fetal, maternal, and infant outcomes through 12 months of age.
What is being tested
- Rimegepant (other)
- Not taking Rimegepant (other)
Sponsor: Pfizer · Participants: 780 · Started: Sep 23, 2021
Contact the study team
- Pfizer Pfizer CT.gov Call Center · Phone: 1-800-718-1021
Official record on ClinicalTrials.gov — NCT05046613
Locations in the U.S.
| North Carolina | Evidera, a PPD business unit, Wilmington |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.